Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GV-Flu Seasonal
- Development stage
- Preclinical
- Lead developer
- GreenVax
- Modality
- Vaccines & Immunotherapeutics
01
Overview
GV-Flu Seasonal (GEV-001) is an inactivated seasonal influenza vaccine candidate developed by GreenVax. It is designed to prevent seasonal influenza and associated acute respiratory illnesses in both the general population and the elderly (aged 65 and older). The vaccine is produced using GreenVax's proprietary B cell T cell Collaboration (BTC) platform, which utilizes epigallocatechin gallate (EGCG)—a natural polyphenol derived from green tea—as an inactivating agent instead of traditional formaldehyde. This approach is designed to minimize damage to the native antigenic structure of the virus, thereby eliciting a more robust and balanced humoral (B cell) and cellular (T cell) immune response.
- Other names
- GV-Flu-plus 65GV-Flu-plus65GV-Flu-plus-65
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on GV-Flu Seasonal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GV-Flu Seasonal.